pazopanib / Generic mfg. - LARVOL DELTA

Molecular profiling in pazopanib-treated metastatic soft tissue sarcoma (STS) (ESMO 2026) - No abstract available

Metastases • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

A Phase II Clinical Trial of IBR854 (A 5T4-Antibody NK Cell Conjugation) Injection Combined with Pazopanib for the Treatment of Advanced Renal Cell Carcinoma (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Characteristics, Management, and Outcomes of Localized Chondrosarcoma: A Single-Institution Retrospective Study (ASTRO 2026) - "16.7% of patients received systemic therapy, most frequently Pazopanib (58.8%)... In this large, single-institution cohort of patients with localized CS, surgical margins status, histologic subtype, and grade were key determinants of outcome. Whereas risk of local recurrence was present across grade and histologic subtype, but was strongly associated with surgical margin status, risk of distant metastasis and overall survival was highly associated with dedifferentiated histology and high-grade pathology. These findings support aggressive pursuit of negative-margin surgical resection and risk-adapted, subtype-specific adjuvant therapy strategies, and highlight the need for prospective studies evaluating the role of systemic and radiation therapies in high-risk CS."

Retrospective data • Oncology • Sarcoma • Solid Tumor

Balancing Bleeding and Ablation: Refractory HHT-Related Small Bowel Bleeding Despite Multimodal Therapy (ACG 2026) - "Management includes iron replacement, transfusion support, endoscopic ablation, antifibrinolytics for mild disease, and systemic anti-angiogenic therapy like bevacizumab for moderate-to-severe disease, with pazopanib emerging as an option...Tranexamic acid and intramuscular octreotide had not provided adequate symptom control...Double-balloon enteroscopy demonstrating numerous small bowel telangiectasias in the duodenum (AâB) and proximal jejunum (CâD). Approximately 30 lesions were identified, predominantly in the proximal jejunum, and treated with argon plasma coagulation."

Gastroenterology • Hematological Disorders

Suspected Ampalaya-Induced Acute Pancreatitis and Hepatitis in a 70-Year-Old Woman: A Case Report (ACG 2026) - "Although generally regarded as safe, its potential for hepatotoxic or pancreatic injury remains poorly characterized, with only one previously documented case of pancreatitis associated with concurrent pazopanib therapy...Current medications included alendronate 70 mg weekly, apixaban 2.5 mg twice a day, cholecalciferol 2000 unit daily, fish oil 1000 mg daily, levothyroxine 112 mcg daily, magnesium glycinate 240 mg daily, rosuvastatin 5 mg daily...This case suggests a probable association between ampalaya ingestion and acute pancreatitis with concomitant hepatocellular injury. Given the widespread use of Momordica charantia for diabetes management, clinicians should maintain a high index of suspicion for herbal-supplement induced pancreatic and hepatic toxicity when more common etiologies have been excluded."

Case report • Clinical • Diabetes • Gastroenterology • Hepatology • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Pancreatitis • Type 2 Diabetes Mellitus

Endoscopic UltrasoundâGuided Radiofrequency Ablation of Metastatic Pancreatic Rhabdomyosarcoma in a Pediatric Patient: First Reported Case (ACG 2026) - "The patient was not a candidate for resection and had achieved the maximal radiation dose due to prior radiation to the tumor, thus she was maintained on pazopanib...(E) Repeat EUS-RFA. (F) Post-ablation decrease (20Ã14 mm)."

Clinical • Metastases • Pancreatitis • Pediatrics • Pruritus • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Volcano-Like Lesions and Diffuse Gastrointestinal Metastases From Leiomyosarcoma Presenting With Melena (ACG 2026) - "He was treated with dacarbazine with a significantly good response, but was discontinued after ten months due to adverse effects. He then started on trabectedin; however, the follow-up imaging one year later demonstrated disease progression...The patient started on pazopanib and palliative radiation therapy...Prognosis remains poor once GI involvement occurs. Figure: Endoscopic images of GI Tract Involvement with Leiomyosarcoma: Section A: Colon leiomyosarcoma Section B: Duodenal leiomyosarcoma Section C: Stomach leiomyosarcoma Section D: Multiple lesions (LMS) involving the stomach Figure: Histopathological Images: Section A: Leiomyosarcoma involving colonic mucosa, consisting of perpendicularly oriented fascicles of brightly eosinophilic spindle cells Section B: CD117/kit is negative in the leiomyosarcoma, highlighting only scattered mast cells (immunoperoxidase, original magnification 20x) Section C: There is a strong diffuse expression of caldesmon (immunoperoxidase,..."

Gastric Cancer • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Leiomyosarcoma • Sarcoma • Solid Tumor • ANO1 • CALD • KIT

Progression-Free Survival With Second, Third, and Fourth Line Tyrosine Kinase Inhibitors After Imatinib Failure in Gastrointestinal Stromal Tumors: A Genetic Mutation-Stratified Systematic Review and Meta-Analysis (ACG 2026) - "Masitinib did not improve PFS versus sunitinib. In the VOYAGER trial, avapritinib did not improve progression-free survival compared with regorafenib in the overall study population, but it showed activity in patients with PDGFRA D842V mutations... 11 randomized trials including 2,181 patients with advanced gastrointestinal stromal tumors after imatinib failure were included. Overall, active TKIs significantly improved progression-free survival (PFS) compared with placebo or best supportive care (HR 0.32, 95% CI 0.21â0.51) although heterogeneity was substantial. Sunitinib, regorafenib, ripretinib, pazopanib, and imatinib rechallenge showed benefit in delaying disease progression compared with placebo or best supportive care, whereas Nilotinib did not with best supportive care, with or without imatinib or sunitinib."

Retrospective data • Review • Stroma • Gastrointestinal Stromal Tumor • Oncology • Sarcoma • KIT • PDGFRA

Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors. (PubMed, Clin Pharmacokinet) - "Target attainment was suboptimal for most TKIs, supporting the need for TDM-guided optimisation and individualised dosing. Associations between TKI exposure and renal, hepatic, and haematological parameters further support personalised treatment strategies."

Journal • PK/PD data • Hematological Disorders • Oncology

Investigating Real-World Tolerance and Dose Reductions of Oncology Multikinase Inhibitors in a VA Population. (PubMed, Fed Pract) - "Individual mean RDIs were 71.0% for axitinib, 59.6% for cabozantinib, 63.7% for lenvatinib, 82.3% for pazopanib, 61.2% for regorafenib, 49.0% for sorafenib, and 85.5% for sunitinib...Oncology MKI therapies used at VANTHCS were difficult for veterans to tolerate and ultimately led to suboptimal dosing. Clinicians may use these data to guide decision-making when initiating and managing MKI agents in this population."

Journal • Real-world evidence • Hematological Disorders • Oncology

Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial. (ASCO-GU 2023) - P2 | "Background: To date, no biomarker of efficacy of nivolumab+/-ipilimumab (N+/-I) or anti-VEGFR TKI has been prospectively validated in mRCC...The most frequent L2 received after N+/-I was a TKI in 96/102 (94%) pts, including cabozantinib in 49, sunitinib/pazopanib in 32, axitinib in 13, and lenvatinib in 2... We report for the first-time OS and L2 efficacy results by molecular group in a randomized trial. Molecular selection also has an impact on treatment efficacy in L2. These results, together with those reported in L1, can inform clinicians on the best treatment sequence in L1-2."

Clinical • Metastases • P2 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Use of receptor and nonreceptor tyrosine kinase inhibitors and Parkinson disease risk. (PubMed, Neurotherapeutics) - "This study investigated associations between Medicare Part D prescription fills prior to PD diagnosis for 7 rTK inhibitors (erlotinib, sorafenib, pazopanib, imatinib, sunitinib, nintedanib, and dasatinib) and 4 nrTK inhibitors (nilotinib, ibrutinib, ruxolitinib, and tofacitinib) and PD risk. Given the chemotherapeutic mechanisms of these medications, and the known cancer-PD inverse relationship, we performed a sensitivity analysis adjusting for relevant cancer subtypes, yielding a similar inverse association. Overall, the use of rTK and nrTK inhibitors was associated with a lower risk of developing PD, although there may be differential impact of this medication class depending on specific inhibition pathways."

Journal • CNS Disorders • Movement Disorders • Oncology • Parkinson's Disease

A case of recurrent acute acalculous cholecystitis in a patient with renal cell carcinoma treated with pazopanib and axitinib: case report and literature review. (PubMed, Front Pharmacol) - "The study suggests that anti-angiogenic tyrosine kinase inhibitors may induce rare episodes of cholecystitis in specific patient populations. Clinicians should maintain adequate vigilance, conduct close clinical monitoring, and adjust therapeutic regimens in a timely manner to ensure patient safety and optimize prognosis."

Journal • Gastroenterology • Genito-urinary Cancer • Hepatology • Oncology • Renal Cell Carcinoma • Solid Tumor

Comprehensive Profiling of ac4C RNA Modification Identifies CERCAM in Cancer-Associated Fibroblasts as a Key Prognostic and Microenvironmental Regulator in Colorectal Cancer. (PubMed, Cancer Rep (Hoboken)) - "This study delineates the crucial role of ac4C modification in shaping the CRC microenvironment, identifies CERCAM as a CAF-specific driver of tumor progression, and provides a translational framework for ac4C-based prognostic prediction and personalized targeted therapy."

Biomarker • IO biomarker • Journal • Colorectal Cancer • Oncology • Solid Tumor • CAFs • CD14 • CD8 • LAG3 • SIRPA • TGFB1

Current Paradigm Shift in the Treatment of Hereditary Hemorrhagic Telangiectasia: A Narrative Review. (PubMed, Cerebrovasc Dis) - "Antiangiogenic agents including intravenous bevacizumab, pomalidomide, thalidomide, and oral pazopanib have demonstrated efficacy in reducing bleeding severity, improving hemoglobin levels, and decreasing transfusion requirements in moderate-to-severe disease. Advances in antiangiogenic and precision-medicine approaches are improving bleeding control and long-term outcomes. Early recognition, comprehensive screening, individualized therapy, and coordinated management across specialties are critical for optimizing care in this complex multisystem disease."

Journal • Review • Cardiovascular • CNS Disorders • Gastroenterology • Hematological Disorders • ACVRL1 • ALK1 • ENG • SMAD4 • TGFB1

Final results of a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin, and pazopanib: 2ND-STEP study, JCOG1802. (ASCO 2026) - "Funded by Japan Agency for Medical Research and Development (AMED) Clinical Trial Registration Number: jRCTs031190152 Background: The optimal second-line treatment for advanced soft tissue sarcomas (STS) after doxorubicin therapy remains unclear. This trial aimed to identify the most promising agent among trabectedin, eribulin, and pazopanib for subsequent phase III comparison against gemcitabine plus docetaxel (GD), which has traditionally been considered a standard treatment... Consistent with the primary analysis, pazopanib generally showed favorable PFS, OS, and DCR among the three agents. Based on these results, pazopanib was identified as the most appropriate candidate to be compared with GD in a phase III trial, which is currently being planned."

Clinical • Metastases • P2 data • Leiomyosarcoma • Liposarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Association of Prior Local Therapy with Outcomes Within Systemic Therapy Regimen Cohorts in Advanced Soft Tissue Sarcoma: A Retrospective Cohort Study. (PubMed, Cancers (Basel)) - " This retrospective cohort included 75 patients with recurrent or metastatic STS who contributed 155 treatment episodes: doxorubicin (n = 44), trabectedin (n = 31), pazopanib (n = 42), and eribulin (n = 38). No between-regimen differences were formally tested. These findings support individualized multidisciplinary assessment and external validation."

Journal • Retrospective data • Leiomyosarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group. (PubMed, JCO Glob Oncol) - "In this real-world cohort, although TKIs were associated with limited survival outcomes, they had an acceptable safety profile in patients with advanced bone sarcomas. These findings are consistent with the results of phase II studies and suggest that TKIs may be a treatment option for patients who have disease progression after standard therapies."

Journal • Real-world evidence • Retrospective data • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Cutaneous Angiosarcoma: A Case Highlighting the Dismal Prognosis of an Aggressive Malignancy (SOHO 2026) - "In advanced stages, immune checkpoint inhibitors such as pembrolizumab, nivolumab, and ipilimumab, as well as targeted therapies including pazopanib and sorafenib, have shown promising clinical responses and survival benefits...In the absence of immunotherapy and targeted agents in Venezuela, treatment was limited to epirubicin, ifosfamide, and mesna... This case highlights the fulminant course and devastating prognosis of unresectable cutaneous angiosarcoma while emphasizing the therapeutic limitations faced in resource-constrained settings. CD: cluster of differentiation, FLI-1: Friend leukemia integration 1 transcription factor."

Clinical • IO biomarker • Angiosarcoma • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Non-melanoma Skin Cancer • Oncology • Sarcoma • Solid Tumor • CD31 • FLI1 • PECAM1

Final results of the RAR-IMMUNE study: A randomized, comparative, prospective, multicenter phase III trial of the efficacy of nivolumab + ipilimumab (N+I) versus pazopanib (P) in patients (pt) with advanced sarcoma (S) of rare subtype (ESMO 2025) - P3 | "Conclusions The study did not reach its primary endpoint, with no significant difference in PFS between the two arms. The safety profile was better with N+I than with P. QoL will be presented at the congress."

Clinical • Late-breaking abstract • Metastases • P3 data • Angiosarcoma • Chordoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

A Patient-Derived Pharmacogenomic Platform Reveals Therapeutic Trajectories and Context-Specific Vulnerabilities in Refractory Lung Cancer (IASLC-WCLC 2026) - "The T1 subtype showed sensitivity to the multi-targeted TKI pazopanib, suggesting its potential to prevent disease progression...Furthermore, the therapeutic candidates predicted for the immune-active T2 subtype were consistent with outcomes reported in clinical trials investigating combination immunotherapy strategies. Conclusions : These findings demonstrate that the PDC-based pharmacogenomic platform can capture dynamic therapeutic trajectories, reveal context-specific drug vulnerabilities, and provide a practical framework for precision therapeutic prediction in refractory lung cancer."

Biomarker • Clinical • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR • TP53

Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. (PubMed, J Clin Oncol) - P2/3 | "Eight-five eligible patients were randomly assigned to receive (regimen A) or not receive (regimen B) pazopanib in combination with ifosfamide and doxorubicin + preoperative radiotherapy followed by primary resection at week 13 and then further chemotherapy at week 25. As of December 31, 2021, at a median survivor follow-up of 3.3 years (range, 0.1-5.8 years), the 3-year event-free survival for all patients in the intent-to-treat analysis was 52.5% (95% CI, 34.8 to 70.2) for regimen A and 50.6% (95% CI, 32 to 69.2) for regimen B (P = .8677, log-rank test); the 3-year overall survival was 75.7% (95% CI, 59.7 to 91.7) for regimen A and 65.4% (95% CI, 48.1 to 82.7) for regimen B (P = .1919, log-rank test). Although the rate of near complete pathologic response was significantly greater with the addition of pazopanib, outcomes were not statistically significantly different between the two regimens."

Journal • Oncology • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. (PubMed, J Clin Oncol) - "Pazopanib did not improve DFS as the primary end point compared with blinded placebo in patients with mRCC with NED after metastasectomy. In addition, there was a concerning trend favoring placebo in OS."

Clinical • Journal • Metastases • P3 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Outcomes and Subsequent Treatment Patterns from a Resource-Constrained Setting in South India. (PubMed, J Kidney Cancer VHL) - "No treatment-related deaths were reported. Reduced-dose pazopanib appears to be a feasible first-line treatment option for anti-VEGF treatment-naïve patients with mRCC who are unable to access immunotherapy, providing clinically meaningful efficacy with a favorable toxicity profile."

Journal • Real-world evidence • Cardiovascular • Dermatology • Genito-urinary Cancer • Hypertension • Oncology • Renal Cell Carcinoma • Solid Tumor

Nucleolar METTL16 drives ccRCC tumorigenesis and pazopanib resistance via translational activation of JAG1/Notch signaling pathway. (PubMed, Drug Resist Updat) - "A novel small-molecule inhibitor targeting the METTL16 methyltransferase activity pocket, METTL16-IN, markedly suppressed resistant tumor growth and synergized with pazopanib to reverse TKI resistance. Our findings support a model in which METTL16-mediated m6A remodeling contributes to pazopanib resistance through altered ribosome biogenesis and translational reprogramming."

Journal • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • JAG1 • METTL16